CLL

Reni Benjamin of Raymond James maintains a Strong Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) after hosting an investor meeting with Charles Farber, a notable physician at the Summit Medical Group. Benjamin noted Farber's practice treats approximately 80 patients per week who suffer from...

H.C. Wainwright maintains Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) as it welcomes the company’s amendment of a cancer study called GENUINE. Under GENUINE, TG is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in patients with previously treated high-risk...